share_log

Leading Operations Executive Adi Shemer Joins AppYea's Advisory Board

Leading Operations Executive Adi Shemer Joins AppYea's Advisory Board

首席運營主管阿迪·謝默加入 AppYea 的顧問委員會
Accesswire ·  2023/02/16 09:26

GAN YAVNE, ISRAEL / February 16, 2023 / AppYea Inc. (OTCQB:APYP), a developer of accurate wearable monitoring solutions to treat sleep apnea and snoring, is pleased to announce the addition of Adi Shemer to the advisory board of the Company, effective immediately.

GAN YAVNE,以色列 /2023 年 2 月 16 日/AppYea Inc. (OTCQB: APYP), 治療睡眠呼吸暫停和打鼾的精確可穿戴監測解決方案的開發商很高興地宣佈,Adi Shemer加入公司顧問委員會,立即生效。

Mr. Shemer brings extensive experience in senior operations, management and control of production processes, establishment, and management of logistics systems. Mr. Shemer established and managed marketing and distribution channels in the USA and Europe, mainly in the field of medical devices. Mr. Shemer has served in key senior executive roles including CEO at TR bike Ltd, CEO at Tzora Active Systems Ltd., and as Director of U.S. Operation at Moving Life Ltd. Mr. Shemer has a BSC degree in industrial and management engineering from Ariel University.

Shemer 先生在高級運營、生產過程的管理和控制、物流系統的建立和管理方面擁有豐富的經驗。Shemer 先生在美國和歐洲建立並管理營銷和分銷渠道,主要集中在醫療器械領域。謝默先生曾擔任過重要的高級管理職務,包括TR bike Ltd的首席執行官、Tzora Active Systems Ltd.的首席執行官和Moving Ltd.的美國運營總監。Shemer先生擁有愛麗兒大學的工業和管理工程學士學位。

Mr. Shemer stated, "I am excited to join AppYea and look forward to playing an active role in helping enhance the production and distribution of DreamIT, which I believe will dramatically change the quality of sleep for millions of people across the world. I look forward to contributing my experience in the field of international distribution and logistics, as the company transitions from a development stage to fully commercial operations."

謝默先生說, “我很高興加入AppYea,並期待在幫助加強DreamIt的製作和發行方面發揮積極作用,我相信這將極大地改變全球數百萬人的睡眠質量。隨着公司從開發階段過渡到全面商業運營,我期待貢獻我在國際分銷和物流領域的經驗。”

Boris (Bary) Molchadsky, Chairman and CEO of AppYea, further noted, "I am pleased to welcome Adi to the advisory board given his successful track record. I am convinced that Adi's experience will be invaluable as we advance our commercial strategy, including the development of new sales and distribution channels. The feedback from the market thus far has been extremely encouraging and we look forward to this next phase in our evolution."

AppYea董事長兼首席執行官鮑里斯(巴里)莫爾查德斯基進一步指出, “鑑於阿迪的成功往績,我很高興歡迎他加入顧問委員會。我堅信,在我們推進商業戰略,包括開發新的銷售和分銷渠道的過程中,阿迪的經驗將是無價的。到目前爲止,市場的反饋非常令人鼓舞,我們期待着下一階段的發展。”

About SleepX

關於 SleepX

SleepX is the research and development subsidiary of AppYea. The Company has developed a unique product for monitoring and treating sleep apnea and snoring. The technology is protected by several international patents. The Company currently focuses its activities on commercialization of its first product, DreamIT.

SleepX 是 AppYea 的研發子公司。該公司開發了一種用於監測和治療睡眠呼吸暫停和打鼾的獨特產品。該技術受到多項國際專利的保護。該公司目前的活動重點是其第一款產品的商業化, DreamIt

About AppYea

關於 AppYea

AppYea is a Healthtech company commercializing a breakthrough wearable technology for the treatment of snoring and developing wearable solutions to diagnose and treat sleep apnea. The company's solutions are based on its proprietary IP portfolio of AI and sensing technologies for the tracking and analysis of breathing patterns, vital signs and other physiological parameters during sleep, designed for greater accuracy at lower and affordable cost.

AppYea是一家健康科技公司,正在將一種用於治療打鼾的突破性可穿戴技術商業化,並開發用於診斷和治療睡眠呼吸暫停的可穿戴解決方案。該公司的解決方案基於其專有技術 知識產權投資組合 用於跟蹤和分析睡眠期間的呼吸模式、生命體徵和其他生理參數的人工智能和傳感技術,旨在以更低且負擔得起的成本提高準確性。

Cautionary Note Regarding Forward-Looking Statements

關於前瞻性陳述的警示說明

Statements included in this press release, which are not historical in nature, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements relating to the future performance of AppYea are subject to many factors including, but not limited to, the sufficiency or working capital and our ability to raise the capital needed to fund our development efforts, timing of product development, FDA approval/clearance of products in development, customer acceptance of our products in the market, the introduction of competitive products, the impact of any product liability or other adverse litigation, commercialization and technological difficulties, and the other risks identified in the S-1 resale registration statement filed with the Securities and Exchange Commission. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof, and we do not undertake any obligation to update any forward-looking statements, whether as a result of future events, new information, or otherwise.

本新聞稿中包含的聲明本質上不是歷史性的,是根據1995年《私人證券訴訟改革法》的安全港條款作出的前瞻性陳述。與AppYea未來業績有關的陳述受許多因素的影響,包括但不限於充足的資金或營運資金以及我們籌集開發工作所需資金的能力、產品開發時機、美國食品藥品管理局對開發產品的批准/批准、客戶對我們產品在市場的接受程度、競爭產品的推出、任何產品責任或其他不利訴訟的影響、商業化和技術困難以及S-1中確定的其他風險轉售向證券交易委員會提交的註冊聲明。此類陳述基於管理層當前的信念和期望,存在重大風險和不確定性。實際結果可能與前瞻性陳述中列出的結果不同。本新聞稿中包含的前瞻性陳述自本文發佈之日起作出,我們沒有義務更新任何前瞻性陳述,無論是由於未來事件、新信息還是其他原因。

Contact:

聯繫人:

Crescendo Communications, LLC
Tel: (212) 671-1020
Email: APYP@Crescendo-IR.com

克雷森多通訊有限責任公司
電話:(212) 671-1020
電子郵件:APYP@Crescendo-IR.com

SOURCE: AppYea Inc.

來源: AppYea Inc.


View source version on accesswire.com:
在 accesswire.com 上查看源代碼版本:

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論